Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals Inc. (GB:0A4W)
:0A4W
RESEARCH TOOLSreports
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.14Last Year’s EPS
0.2Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 0.00%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant revenue growth in key products and accelerated progress in the pipeline, despite some challenges with sequential sales decline and increased R&D expenses.Company Guidance
During ACADIA Pharmaceuticals' first quarter 2025 conference call, the company outlined its strong financial performance and strategic initiatives. The call highlighted a 19% increase in total revenue, reaching $244.3 million, with DAYBUE and NUPLAZID sales rising by 11% and 23%, respectively. DAYBUE achieved $84.6 million in sales with 954 unique patients, while NUPLAZID recorded $159.7 million in revenue. The persistency rate for DAYBUE remained above 50% after 12 months, and NUPLAZID benefited from a one-time gross-to-net adjustment. The company reiterated its full-year guidance for both products and raised its R&D expense projection to $330-350 million. ACADIA also accelerated its COMPASS PWS Phase 3 study timeline, expecting results by the end of 2025. Internationally, plans are underway for DAYBUE's European launch, with anticipated EMA approval in early 2026. The company emphasized its commitment to strategic priorities, including expanding its commercial reach and advancing its pipeline.Strong Revenue Growth
First quarter 2025 revenues reached $244.3 million, up 19% from the previous year.
DAYBUE Sales Increase
DAYBUE sales were $84.6 million in the first quarter, marking an 11% increase from the previous year with 954 unique patients, an all-time record for the brand.
NUPLAZID Revenue Growth
NUPLAZID reported first quarter sales of $159.7 million, up 23% from the prior year, with 6% growth in volume.
Accelerated Pipeline Progress
The timeline for the COMPASS PWS Phase 3 trial has accelerated, with top-line results expected by early fourth quarter 2025.
European Expansion Plans
Preparations for European launch of DAYBUE are underway, with regulatory approval anticipated in Q1 2026.
GB:0A4W Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0A4W Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $18.62 | $18.62 | 0.00% |
Feb 26, 2025 | $18.62 | $18.62 | 0.00% |
Nov 06, 2024 | $15.68 | $17.26 | +10.08% |
Aug 06, 2024 | $18.90 | $15.49 | -18.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ACADIA Pharmaceuticals Inc. (GB:0A4W) report earnings?
ACADIA Pharmaceuticals Inc. (GB:0A4W) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is ACADIA Pharmaceuticals Inc. (GB:0A4W) earnings time?
ACADIA Pharmaceuticals Inc. (GB:0A4W) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of ACADIA Pharmaceuticals Inc. stock?
The P/E ratio of ACADIA Pharmaceuticals is N/A.
What is GB:0A4W EPS forecast?
GB:0A4W EPS forecast for the fiscal quarter 2025 (Q2) is 0.14.